Pay for Delay


Or as I call it “Pay Not To Play”. Industry insiders are closely watching the Supreme Court case involving the FTC vs Actavis/AndroGel. Seems that this manufacturer of testosterone cream paid hundreds of millions of dollars to three generic companies to not challenge the AndroGel patent and therefore not bring a generic alternative to market. The government is arguing that this splitting of monopoly profits is illegal and consumers are being injured.

I do not claim to understand all of the nuances of antitrust and constitutional case law. What I do understand is that anytime Big Pharma seems to have a problem, civil penalty or roadblock, they simply reach over in the petty cash drawer to write a check to make it all better.

Wonder where these profits come from?

Call Us. We can do better.

William Faris, JD
Chief Executive Officer

Posted in OMCA